



## OPEN ACCESS

EDITED AND REVIEWED BY  
Santiago Viteri,  
Clínica Mi Tres Torres, Spain

## \*CORRESPONDENCE

Xingya Li  
✉ [lixingya0925@vip.163.com](mailto:lixingya0925@vip.163.com)  
Huixian Zhang  
✉ [huixianeight@163.com](mailto:huixianeight@163.com)

†These authors have contributed equally to this work

RECEIVED 05 April 2024

ACCEPTED 28 May 2024

PUBLISHED 03 June 2024

## CITATION

Yan N, Guo S, Huang S, Zhang H and Li X (2024) Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience. *Front. Oncol.* 14:1412472. doi: 10.3389/fonc.2024.1412472

## COPYRIGHT

© 2024 Yan, Guo, Huang, Zhang and Li. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

Ningning Yan<sup>†</sup>, Sanxing Guo<sup>†</sup>, Siyuan Huang, Huixian Zhang\* and Xingya Li\*

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

## KEYWORDS

furmonertinib, non-small cell lung cancer, EGFR-mutated, epidermal growth factor, receptor, real-world setting

## A Corrigendum on

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience


by Yan N, Guo S, Huang S, Zhang H and Li X (2024). *Front. Oncol.* 14:1331128. doi: 10.3389/fonc.2024.1331128

In the published article, there was an error in the legend for [Figure 2](#) as published. Furthermore, we have made the wrong graphical representation for [Figure 2](#). The corrected figure and its legend appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



**FIGURE 2** PFS of total population and patients with evaluable brain metastases. **(A)** PFS of all the patients treated with furmonertinib. **(B)** the median intracranial PFS of patients with brain metastases treated with furmonertinib. PFS, progression-free survival.